mpus America, Inc.; STERIS Corporation - U.S. Endoscopy; and EndoChoice, Inc. The company’s patient monitoring offering includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs. The company also offers a line of suction instruments and tubing for use in the operating room, as well as a line of IV products for use in the critical care areas of the hospital. This offering competition includes Medtronic plc: Covidien Ltd: Kendall and 3M Company. Surgical Visualization The company’s surgical visualization product line offers imaging systems for use in minimally invasive orthopedic and general surgery procedures, including 2DHD and 3DHD vision technologies. Competition includes Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Olympus, Inc.; and Karl Storz GmbH. International The company’s products are sold in approximately 100 foreign countries. International sales efforts are coordinated through local country dealers or through direct in-country sales. The company distributes its products through sales subsidiaries and branches with offices located in Australia, Austria, Belgium, Canada, China, Denmark, Finland, France, Germany, Italy, Korea, the Netherlands, Poland, Spain, Sweden, and the United Kingdom. Marketing A portion of the company’s products are distributed domestically directly to approximately 6,000 hospitals and other healthcare institutions, as well as through medical specialty distributors and surgeons. A portion of the company’s U.S. sales are to customers affiliated with group purchasing organizations, integrated delivery networks, and other large national or regional accounts, as well as to the Veterans Administration and other hospitals operated by the Federal government. For hospital inventory management purposes, some of the company’s customers prefer to purchase its products through independent third-party medical product distributors. The company’s health systems organization is responsible for interacting with large regional and national accounts (group purchasing organizations, integrated delivery networks, etc.). Business Strategy The company’s business strategy includes the introduction of new products and product improvements; pursuing strategic acquisitions; realizing manufacturing efficiencies; geographic diversification; and active participation in the medical community. Research and Development Amounts expended for the company’s research and development were approximately $27.8 million during 2014. Intellectual Property The development, manufacture, sale and distribution of the company’s products are subject to regulation by various agencies and legislative bodies, including the U.S. Food and Drug Administration and comparable foreign counterparts. In the United States, these regulations are enacted under the Medical Device Amendments of 1976 to the Federal Food, Drug and Cosmetic Act and its subsequent amendments, and the regulations issued or proposed thereunder. History CONMED Corporation was founded in 1970. The company was incorporated under the laws of the state of New York in 1970 by Eugene R. Corasanti.
(CNMD:Consolidated Issue Listed on NASDAQ Global Select )
525 French Road
Utica, NY 13502
|Ascom Holding AG||SFr.17.55 CHF||-0.10|
|Integra LifeSciences Holdings Corp||$64.56 USD||+0.56|
|Masimo Corp||$41.87 USD||+0.18|
|NuVasive Inc||$54.99 USD||+0.06|
|Wright Medical Group Inc||$26.06 USD||+0.06|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.